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The relationship between late normal tissue radiation injury phenotypes in 167 breast cancer patients treated with radiotherapy and:
(i) radiotherapy dose (boost); (ii) an early acute radiation reaction and (iii) genetic background was examined. Patients were
genotyped at single nucleotide polymorphisms (SNPs) in eight candidate genes. An early acute reaction to radiation and/or the
inheritance of the transforming growth factor-b1( TGFb1  509T) SNP contributed to the risk of fibrosis. In contrast, an additional
15Gy electron boost and/or the inheritance of X-ray repair cross-complementing 1 (XRCC1) (R399Q) SNP contributed to the risk
of telangiectasia. Although fibrosis, telangiectasia and atrophy, all contribute to late radiation injury, the data suggest that they have
distinct underlying genetic and radiobiological causes. Fibrosis risk is associated with an inflammatory response (an acute reaction and/
or TGFb1), whereas telangiectasia is associated with vascular endothelial cell damage (boost and/or XRCC1). Atrophy is associated
with an acute response, but the genetic predisposing factors that determine the risk of an acute response or atrophy have yet to be
identified. A combined analysis of two UK breast cancer patient studies shows that 8% of patients are homozygous (TT) for the
TGFb1 (C-509T) variant allele and have a 15-fold increased risk of fibrosis following radiotherapy (95% confidence interval: 3.76–
60.3; P¼0.000003) compared with (CC) homozygotes.
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Radiotherapy is associated with a wide spectrum of normal-tissue
reactions, and as the life expectancy of cancer patients increases,
normal tissue effects are increasingly of clinical importance. Tissue
toxicity may range from asymptomatic changes in tissue structure
and function, to severe cosmetic disfigurement and life-altering
changes in organ function (Bentzen et al, 2003). The effects can be
divided into early/acute reactions, which occur within 90 days of
treatment, and late reactions that occur more than 90 days after
treatment and can persist for life (Van der Kogel, 1993).
Early reactions principally affect high turn-over tissues, such as
skin, the gastrointestinal tract and bone marrow where the onset
and severity of the reactions reflect the balance between the rate
of stem/progenitor-cell killing and the rate of regeneration of
surviving cells (Van der Kogel, 1993). Severe acute reactions are
rare and have been associated with syndromes such as Ataxia
Telangiectasia and Nijmgen Breakage syndrome that have
inherited highly penetrant and mutant alleles encoding DNA
repair enzymes, although low penetrance alleles in the general
population have also been implicated in cellular radiosensitivity
(Hu et al, 2001; Moullan et al, 2003; Chang-Claude et al, 2005;
Fernet and Hall, 2005).
Late effects typically, but not exclusively, manifest in low turn-
over tissues such as lung, heart, liver and the nervous system that
are comparatively depleted of stem and progenitor cells. Common
late manifestations include fibrosis, telangiectasia and atrophy,
and a particular tissue or organ may show signs of one or more
of these reactions at different times following the radiotherapy
(O’Sullivan and Levin, 2003). A significant number of patients
(B5%) show late normal tissue damage, so there are presumably
genetic component(s) that contribute(s) to the risk and severity of
the late tissue radiation effects in the general population.
Transforming growth factor-b1 (TGFb1) is the major cytokine
responsible for the regulation of fibroblast proliferation and
differentiation (Randall and Coggle, 1995; Gauldie et al, 2003;
O’Sullivan and Levin, 2003). Differentiated fibroblasts synthesise
the collagens and proteoglycans in the extracellular matrix, and it
has been suggested that an increase in these fibroblasts may cause
the fibrotic phenotype (Mauch and Kreig, 1990; Martin et al, 2000;
O’Sullivan and Levin, 2003). Radiation induces long-term TGFb1
overexpression probably owing in part to oxidative stress and an
inflammatory response (Randall and Coggle, 1995; Anscher et al,
1997; Martin et al, 1997, 2000; O’Sullivan and Levin, 2003), and a
causal relationship between increased TGFb production and the
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sdevelopment of tissue fibrosis has been reported in animal models
(Zugmaier et al, 1991; Terrell et al, 1993; Sanderson et al, 1995;
Clouthier et al, 1997). Most significantly, elevated serum TGFb1
levels were correlated with an increased risk of fibrosis in breast
and lung cancer patients (Awad et al, 1988; Anscher et al, 1997;
Grainger et al, 1999; Li et al, 1999) and a comparison of the
genotypes of unaffected and affected patients has been genetically
associated with functional polymorphisms in the TGFb1 gene
(Awad et al, 1988; El-Gamel et al, 1999; Quarmby et al, 2003;
Andreassen et al, 2005).
Whether the late tissue effects such as fibrosis, atrophy and
telangiectasia are biologically or radiobiologically related is
controversial. The observation that normal tissue damage can
involve one or combinations of these phenotypes suggests that
their underlying causes may be different. The power of genetic
studies seeking to associate a genotype with a phenotype is
absolutely dependent on the precise definition of the phenotype.
Several scales have been developed, which allow recording of such
injury uniformly and reproducibly, and include the Radiation
Therapy Oncology Group (RTOG) scales, which are relatively
simple to score as each site treated with radiotherapy scores 0–5
according to the degree of injury incurred with an extreme score of
5 indicating patient death (Cox et al, 1995).
The Late Effects of Normal Tissue-Subjective Objective Manage-
ment Analytical (LENT-SOMA) scale allows comparison between
individuals of the clinical perception of injury, the patient’s
perception of the injury, the medical management required and the
underlying pathological process (Pavy et al, 1995). A score of 0–4 is
given to each of the LENT-SOMA tests, and the sum of the individual
scores for each patient a measure of overall tissue damage. However,
the Objective analyses in LENT-SOMA include separate quantitative
measures of fibrosis, atrophy and telangiectasia, so LENT-SOMA
provides a more detailed and specific description of the nature
(phenotype) and severity of the injury/ies than the RTOG scale.
In this report, we have carried out a genetic association study on
breast cancer patients at least 4 years after radiotherapy treatment
who were scored for normal tissue damage using both RTOG and
SOMA scales. The patients were also scored for an early acute
reaction to radiotherapy within 90 days of treatment, and whether
or not they received a 15Gy electron boost. Patients were
genotyped for functional single nucleotide polymorphisms (SNPs)
in eight candidate genes, and thus enabled the analysis of the
relative contribution of radiotherapy schedule, the presence of an
early acute response and genetic background, to the risk of specific
late injury phenotypes.
MATERIALS AND METHODS
Patients and methods
The study has been undertaken with the participation of patients
attending the oncology departments of Leicester Royal Infirmary,
Glenfield Hospital, Leicester and Nottingham City Hospital, UK. Full
ethical and local trust approval was obtained from the relevant
ethics committees and trust Research and Development depart-
ments. All patients gave written informed consent before entry into
the study, and underwent an examination of the affected area and
the recognised features of late radiation effects scored by the SOMA
and/or RTOG scales. Seven patients refused to take part in the study.
Tumour-free breast cancer patients were recruited sequentially
in the follow-up clinic of one consultant in Leicester, UK (IP). The
majority (155/167) were treated more than 4 years previously
(median¼6.1 years), but 12 additional patients who were known
to have late effects were examined at the City hospital, Nottingham
(n¼5), and the Leicester Royal Infirmary (n¼7), UK between 2.3
and 3.6 years after treatment. All patients were asked about
potential radiosensitising comorbid diseases such as diabetes or
collagen vascular disorders and a family history of abnormal
reactions to radiotherapy. Initial surgery was either a lumpectomy
(n¼116) or mastectomy plus axillary dissection (n¼47). Two
patients had a lumpectomy but then went on to have a
mastectomy, and two had no surgery.
Radiotherapy (6MV X-rays) was given either after mastectomy
or lumpectomy using tangential fields, and all patients received
similar field sizes. All patients also had a 1.5cm thick strip of wax
4cm in width applied to either the lumpectomy or mastectomy
scar to reduce ‘skin sparing’ during every second fraction. A total
of 119 patients received the then standard departmental protocol
of 45Gy in 20 fractions in 4 weeks given to either the breast or
chest wall. Seventy-one of these patients who had been treated by
local excision received a boost of 15Gy in five fractions in 1 week
using 8–12MeV electrons to the site of the lumpectomy. Boost
sizes were between 6 6 and 8 10cm. Ten patients received
40Gy in 15 fractions as part of the START B trial (NCRN Trial
Standardisation of Breast Radiotherapy, 1998). Thirty-three
patients were treated with a whole breast dose of 50Gy in 25
fractions either as part of the START trial or following the
publication of the European Organisation of Cancer Radiotherapy
and Breast Cancer Groups study (EORTC) (Bartelink et al, 2001),
which identified a group of patients (node negative, complete
excision aged o50) who did not require a local boost (Table 1).
The mean age at treatment was 56.92 (range 30–78).
The majority of patients (157/167) were Caucasians, but nine
patients were of Asian descent and one patient of African
Caribbean descent. Twenty-seven patients received anthracyline-
based chemotherapy (two of which also received CMF), and 18
patients received non-anthracyline-based chemotherapy before
radiotherapy, and 151 patients were further treated with tamoxifen
(one stopped during treatment).
Twenty-four patients were positive for an acute reaction within
90 days of treatment, and three of these did not complete the
radiotherapy schedule. However, including the 15Gy boost, only
one of the three acute responders received significantly less
(16.73Gy) than a total 2Gy equivalent dose of 40Gy.
Table 1 Radiotherapy and chemotherapy
No. of patients 15Gy Electron boost no. of patients
Total dose (Gy) No. of fractions
2Gy equivalent
dose (a/b 2) Chemotherapy Tamoxifen No boost Boost
15.75
a 7 16.73 0 1 1 0
34
a 17 34 0 0 0 1
38
a 17 40.64 0 1 0 1
40 15 46.6 2 10 9 1
45 20 47.81 33 109 48 71
48 24 48 1 1 1 0
50 25 50 9 29 33 1
aPatients who did not complete the planned radiotherapy schedule due to a severe early reaction to radiotherapy.
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patients for genetic analysis by means of a buccal swab. DNA was
extracted from the buccal samples using the QIAamp DNA mini kit
(QIAGEN GmbH, Germany), using the standard manufacturers’
protocol. DNA was PCR amplified and analysed for QTG
restriction fragment length polymorphisms using published PCR
primers and PCR conditions, and restriction enzymes: TGFb1 (C-
509T) (Quarmby et al, 2003); X-ray repair cross-complementing 1
(XRCC1; R399Q) and apurinic/apyrimidinic endonuclease (APE-1;
D126E) (Hu et al, 2001); dihydrofolate reductase (DHFR;1 5 b p
intron 1 deletion) (Johnson et al, 2004); the CX3CR1 (G745A)
fractalkine receptor (McDermott et al, 2001); epoxide hydrolase
(Hyl-1; Y113H) (Lebailly et al, 2002); and methionine synthetase
(MS; A2756G) and methylenetetrahydrofolate reductase (MTHFR;
C667T) (Linnebank et al, 2004).
Statistical analysis The G-test was used to examine the relation-
ship between genotype and phenotype. The G-tests are maximum
likelihood statistical significance tests (log-likelihood ratio) using
the William’s correction for small sample size (Sokal and Rohlf,
1995). Allele frequencies were examined by calculating the odds
ratios (OR), with 95% confidence intervals (95% CI), for the
frequency of the polymorphic allele in one group relative to
another.
RESULTS
A total of 167 breast cancer patients that were treated with
radiotherapy were recruited and examined for late normal tissue
damage. The objective SOMA scales (0–4) (Pavy et al, 1995) were
used to score for fibrosis, atrophy and telangiectasia severity
during a detailed physical examination and represent separate
phenotypic measures of late normal tissue damage. The SOMA
scores of 1 represent subtle examiner-dependent changes that are
inconclusive and in this study are either excluded or included in
the group of patients that show no signs (SOMA 0) of a particular
injury phenotype. In contrast, the SOMA scores of 2–4 represent
unambiguous evidence of late tissue injury. Patients were also
scored using the comparatively nonspecific RTOG scales, but were
non-informative in all the association studies performed (data not
shown).
Factors that might influence the risk and severity of late normal
tissue damage include anatomical differences between individuals,
the initial surgery, treatment regimes (whether or not the patient
received chemotherapy or an electron boost), whether the patient
had an early acute reaction and whether the individual patient was
genetically predisposed. Chemotherapy may increase late effects
(Fiets et al, 2003; Shanley et al, 2006) especially anthracycline
containing regimens but the number of patients that received
anthracyline and non-anthracyline-based chemotherapy in this
study is too small for any meaningful statistical analysis to
compare the two chemotherapies (Table 1).
Radiation dose
The majority (165/167) of patients received a very similar total
2Gy dose fraction equivalent (45–50Gy; Table 1), so dose
differences are largely due to whether the patient received an
additional 15Gy electron boost (18/2Gy equivalent). The area
irradiated in all patients was very similar (6 6–8 10cm), and
the late injury phenotypes readily scored within that area by sight
and/or touch.
Excluding the one patient who received significantly less than
45Gy because of a severe acute reaction to radiotherapy (dose
15.75Gy; Table 1), patients who received a 15Gy boost (n¼75)
were compared with patients who did not receive a boost (n¼91)
(Table 2). Patients that manifested no signs of late injury (SOMA
score 0) were compared with patients that clearly showed signs of
late tissue injury (SOMA score 2–3). No association between
fibrosis and the 15Gy boost was observed (P¼0.47) and a similar
result was obtained for atrophy (P¼0.28; data not shown). In
contrast, the 15Gy boost was weakly associated with an increased
risk of telangiectasia (OR 2.4; 95% CI 1.1–5.4; P¼0.033),
consistent with clinical evidence that telangiectasia is usually
confined to the boost-exposed region of the breast.
Late injury severity and early acute reaction
Twenty-five patients had an unusually severe acute reaction
(erythema, moist desquamation) within 90 days of treatment, so
the presence or absence of this early radiation phenotype was
compared with the late objective SOMA scores (Table 3).
Comparing unaffected patients (SOMA score 0) and clearly
affected patients (SOMA score 2–4) indicates that an early acute
reaction increases the risk of long-term fibrosis by an OR of 8.5
(95% CI 2.64–28.5; P¼0.00004), and increases the risk of long-
term atrophy by 4.7 (95% CI 1.25–17.64; P¼0.02). Telangiectasia
as a late normal tissue injury phenotype was not associated with an
early acute reaction.
In conclusion, within the 45–50Gy dose range (20–25 fractions)
used to treat breast cancer patients in this study, an additional
15Gy boost appears to contribute to an increased risk of
telangiectasia. Conversely, a boost does not predispose to fibrosis
(or atrophy) but an acute reaction does. These findings, which are
based on relatively small numbers of patients, are in disagreement
with earlier studies of post-mastectomy patients (Bentzen and
Overgaard, 1991; Bentzen et al, 1993) and thus need to be
independently confirmed.
Genetic association between genotype and phenotype
Patients were genotyped for eight functional SNPs in candidate
genes. All polymorphisms were assessed by PCR amplification of
buccal DNA and analysed using established Restriction Fragment
Length Polymorphisms (RFLP). Transforming growth factor-b1
polymorphisms were confirmed by direct sequencing.
Table 2 Risk of injury phenotypes and the 15Gy electron boost
Fibrosis number of patients
Telangiectasia number of
patients
SOMA
score No boost Boost No boost Boost
0 6 74 76 64 4
1 1 41 81 0 7
28 8 1 1 1 4
3 224 1 0
Table 3 Risk of late injury phenotypes and an early acute reaction
Fibrosis (patients)
Telangiectasia
(patients) Atrophy (patients)
SOMA
score
Not
acute Acute
Not
acute Acute
Not
acute Acute
0 103 12 97 14 99 14
12 9 3 1 2 5 3 4 5
28 8 2 2 3 8 4
32 2 1 1 3 1 2
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those reported in other studies (Hu et al, 2001; McDermott et al,
2001; Lebailly et al, 2002; Quarmby et al, 2003; Johnson et al, 2004;
Linnebank et al, 2004), and all SNPs were in Hardy–Weinberg
equilibrium (Table 4).
The genes and corresponding SNP were chosen because XRCC1
(R399Q) and APE-1 (D126E) have been implicated in DNA repair
(Hu et al, 2001; Chang-Claude et al, 2005; De Ruyck et al, 2005),
TGFb1 (C-509T) and CX3CR1 (G745A) have been implicated in
inflammation and fibrosis (Zugmaier et al, 1991; Randall and
Coggle, 1995; Anscher et al, 1997; Li et al, 1999; Martin et al, 2000;
McDermott et al, 2001; Gauldie et al, 2003), MTHFR (C667T), MS
(A2756G) and DHFR (19bp del intron 1) involved in folate
metabolism (Johnson et al, 2004; Linnebank et al, 2004), epoxide
hydrolase (Hyl1 Y113H) implicated in oxidative stress (Lebailly
et al, 2002), and XRCC1 (R399Q) have been associated with
susceptibility to breast cancer (Moullan et al, 2003). Additionally,
several gene polymorphism have previously been implicated in late
radiation-induced tissue damage (Awad et al, 1988; El-Gamel et al,
1999; Grainger et al, 1999; Quarmby et al, 2003; Andreassen et al,
2005; De Ruyck et al, 2005, 2006; Brem et al, 2006), and TGFb1 and
Hyl1 are induced following exposure to ionising radiation
(Anscher et al, 1997; Martin et al, 1997).
Out of the eight SNP examined, only the TGFb1 (C-509T) and
XRCC1 (R399Q) polymorphisms showed any significant associa-
tion with late tissue injury in this study.
Fibrosis and telangiectasia
Subjective Objective Management Analytical scores for fibrosis
and telangiectasia were analysed by comparing clearly affected
(SOMA score 2–4) and unaffected patients (SOMA score 0 or 0–1).
As shown in Table 5, the TGFb1 (C-509T) polymorphism was
significantly associated with an increased risk of fibrosis, whereas
the XRCC1 (R399Q) polymorphism was significantly associated with
an increased risk of telangiectasia. No significant genetic association
was observed between atrophy and genotype (data not shown).
As the 15Gy boost also appears to increase the risk of
telangiectasia (Table 2), the XRCC1 (R399Q) association was
performed excluding those patients who had received a boost
(n¼75) to determine whether the two risk factors were distinct.
Similarly, an acute reaction to radiotherapy and the TGFb1 C-509T
polymorphism increase the risk of fibrosis (Table 3), so patients
who manifested an acute response were excluded to separate the
two potentially distinct risk factors.
As shown in Table 6, there is a statistically significant excess
of XRCC1 R399Q RQ heterozygotes in patients with telangiectasia
(P¼0.01; G-test), and an excess of TT homozygotes in patients
with fibrosis (P¼0.003; G-test), suggesting that the risk of
telangiectasia and fibrosis as late normal tissue injury phenotypes
is determined by multiple independent factors.
A boost and the XRCC1 (R399Q) polymorphism each contribute
to the risk of telangiectasia, whereas an acute reaction and the
TGFb1(C-509T) polymorphism make independent contributions
to the overall risk of fibrosis. Significantly, although the risk of
fibrosis and atrophy are both associated with an early acute
response to radiotherapy (Table 3), atrophy was not associated
with either the XRCC1 (R399Q) or TGFb1 (C-509T) polymorph-
isms, evidence that additional distinct genetic risk factors underlie
the risk of atrophy as a late radiation injury phenotype.
The reduced sample size reduces the statistical power of any
association, so the results are at best suggestive and require
independent confirmation.
Combined TGFb1 (C-509T) analyses
Quarmby et al (2003), first reported a significant association
between the TGFb1 (C-509T) polymorphism in Caucasian breast
cancer patients who had received a similar radiotherapy dose
(40Gy in 15 fractions) to those used in this study (Table 1).
Fibrosis was also scored using the SOMA scales, so the two studies
are very similar. Quarmby et al (2003) compared patients with
fibrosis (n¼14; SOMA 2–4) to patients without fibrosis (n¼87;
SOMA 0), and our data for the SOMA fibrosis scores can also be
divided into those that clearly show no fibrosis (score 0; n¼115)
and those that unambiguously show signs of fibrosis (scores 2–4;
n¼20). The data for the two studies were therefore combined to
significantly increase the number of patients analysed (n¼236;
Table 7).
Table 4 Variant allele frequencies in the breast cancer patients
SNP
Variant allele
frequency
Hardy–Weinberg
(P)
TGFb-1 C-509T 0.33 0.22
XRCC1 R399Q 0.37 0.51
APE-1 D126E 0.34 0.39
DHFR (del) 0.46 0.35
CX3CR1 G745A 0.28 0.88
Hyl-1 Y113H 0.33 0.25
MS A2756G 0.23 0.09
MTHFR C667T 0.33 0.61
Table 5 Genetic association of the SOMA fibrosis and telangiectasia
scores
G-test. Fibrosis
P Scores compared Patient number
TGFb1 C509T 0.0041 0 vs 2–4 115 vs 20
0.0032 0–1 vs 2–4 147 vs 20
G-test. Telangiectasia
P Scores compared Patient number
XRCC1 399 0.01 0 vs 2–4 111 vs 39
0.006 0–1 vs 2–4 128 vs 39
Table 6 Genotype distributions for fibrosis and telangiectasia excluding patients that received a boost, or manifested an early acute reaction
Telangiectasia: patients who did not receive a boost XRCC1
(R399Q) genotype
Fibrosis: patients who did not show an acute reaction
TGFb1 (C-509T) genotype
Soma score RR RQ QQ CC CT TT
0 33 25 9 49 47 7
2–4 2 9 4 0 7 3
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association (P¼0.00006) with an OR of 3.06 (95% CI: 1.74–5.3) for
patients carrying at least one variant allele (CT or TT) compared
with the homozygous wild-type CC genotype, and therefore this
increased risk applies to B56% (132/236) of breast cancer patients.
Furthermore, the 8% of patients that are homozygous for the
variant allele (TT) carry a much higher risk of fibrosis than CC
homozygotes (OR 14.7; 95% CI 3.8–60.3) and a lesser but still
significant increased risk compared with CT heterozygotes (OR
4.45; 95% CI 1.4–14). Together with the observation that CT
heterozygotes have a 3.3-fold increased risk of fibrosis than CC
homozygotes, it suggests that the increased risk with each variant
allele is additive.
DISCUSSION
Late normal tissue injury in breast cancer patients that have
received standard radiotherapy treatment (40–50Gy) using iso-
effective fractionated schedules, with or without an additional
15Gy boost, is a combination of phenotypes with distinct
underlying causes. For example, the risk of telangiectasia appears
to increase if the patient received a 15Gy boost and this has been
self-evident in the clinic as the telangiectasia is usually confined to
the area of the breast that received the boost. However, there are
also dose-independent genetic risk factors as evidenced by the
association of the XRCC1 (R399Q) DNA repair gene polymorphism
with increased risk of telangiectasia irrespective of the patient
having received a boost. Similarly, the risk of fibrosis appears to
increase if an early acute radiation reaction is observed with 90
days of therapy, but the TGFb1 (C-509T) variant allele is another
major independent genetic contributor to the risk of fibrosis as a
late radiation injury phenotype. Atrophy is also associated with an
early acute radiation response, but as atrophy is not associated
with any of the QTG analysed, including XRCC1 (R399Q) or TGFb1
(C-509T), the identity of the variant gene(s) that predispose
patients to atrophy as a distinct radiation injury phenotype is
unknown. Similarly, the contribution of different chemotherapeu-
tic regimes to risk of late tissue injury could not be addressed in
this study.
Breast cancer is the most common female cancer in the UK and
the prevalence of radiotherapy treatment in this disease is high. In
2000, there were 40470 new cases of this disease in women and it is
estimated that the lifetime risk of women in the UK developing
breast cancer is 1:9 (CRUK, 2004). Radiotherapy substantially
reduces the risk of local recurrence after surgery with a more
modest reduction in cancer mortality offset by an increase in
contralateral breast cancer and cardiac disease, which is more
marked in older trials (EBCTCG, 2005). Virtually, all patients
treated by breast conservation and patients with high risk factors
for local recurrence after mastectomy receive radiotherapy. A
significant proportion (44% in this study) of patients nevertheless
remains at risk of recurrence and therefore receive an additional
15Gy electron boost. Although these therapy schedules have
significantly increased long-term survival, normal tissue radiation
injury lasts a lifetime and is therefore increasingly a factor that
must be considered in treatment choice as it can affect quality of
life.
Telangiectasia in most cases is only unsightly. However, fibrosis
is often associated with painful tender breasts as evidenced by the
significant association of fibrosis and pain in this group of patients
(P¼0.003; data not shown). It is noteworthy that although the
severity of pain rarely exceeds discomfort ameliorated by simple
analgesia, these symptoms are likely to be life-long and affect
quality of life. It is possible that some patients with a high-risk
genotype that predisposes them to late radiation effects could
avoid radiotherapy. In other cases, the advantages of radiotherapy
may outweigh the risks of fibrosis and discomfort and such
patients may need to be warned of the benefits and additional risks
associated with radiotherapy.
Quarmby et al (2003) originally reported an association of the
TGFb1 (C-509T) gene promoter polymorphism and increased risk
of fibrosis as a late radiotherapy injury phenotype. We have
combined the data in both studies (Tables 7 and 8) to more than
double both the total number of patients analysed (n¼236) and
the number of patients with fibrosis (n¼38). This combined
analysis revealed a highly significant three-fold increased risk of
fibrosis following radiotherapy if a breast cancer patient carries
at least one variant TGFb1 ( 509T) allele (P¼0.00006) and this
applies to over 50% of breast cancer patients. Approximately 8% of
breast cancer patients are homozygous (TT) for the variant allele
and they have a 15 fold increased risk of fibrosis (P¼0.000003)
compared to patients that are homozygous for the wild-type allele
(CC). Together with any evidence of an early acute response to
radiotherapy, a patient’s TGFb1 ( 509) genotype might be useful
in predicting the risk of fibrosis in the long term in a significant
number of patients.
One recent study could not replicate the TGFb1 ( 509) SNP
association with fibrosis in a retrospective analysis of breast cancer
patients (Andreassen et al, 2003, 2005, 2006). The reason is unclear
although differences in the two Danish studies (and the UK
studies; Table 7) include the fact that all patients in the latter
Danish 2006, study had mastectomies, were specifically selected
retrospectively because they exhibited fibrosis, and were treated
with higher radiation doses per fraction than the original 2005
study, which used changes in breast appearance as the phenotype.
Thirteen percent of Danish breast cancer patients in the 2006 study
carried the TT genotype (Andreassen et al, 2006), which is higher
than in the UK breast cancer patients as a whole (7–9%, Table 7),
but lower than the 26% of the UK patients that were positive for
Table 7 Combined analysis of the TGFb1 (C-509T) polymorphism and fibrosis
Quarmby et al, 2003 (patients) This study – Table 4 (patients) Combined (patients)
C-509T genotype No fibrosis Fibrosis No fibrosis Fibrosis No fibrosis Fibrosis
CC 45 4 53 2 98 6
CT 40 5 54 14 94 19
TT 2 5 8 4 10 9
Table 8 Risk of fibrosis according to TGFb1 genotype
Odds ratio 95% CI
a P
CC vs (CT+TT) 3.06 1.7–5.3 0.00006
(CC+CT) vs TT 7.27 2.4–21.8 0.00005
CC vs TT 14.7 3.8–60.3 0.000003
CT vs TT 4.45 1.4–14.0 0.007
CC vs CT 3.3 1.2–9.7 0.002
a95% confidence intervals.
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fraction doses used in a significant proportion of the Danish
patients in the 2006 report may be masking any genetic
contribution. Furthermore, as the Danish patients were specifically
selected in a retrospective study (2006), because they exhibited
fibrosis as a late radiation injury, their genotype distribution
cannot be combined with the UK studies (Table 7) where only a
very small proportion of patients were selected and the majority
of patients exhibited no late effects (Tables 2–6) (Quarmby et al,
2003). The precise patient genotype frequencies are not given in
the Danish 2005 publication (Andreassen et al, 2005), so the data
as published cannot be compared or combined with the UK
studies. Nevertheless, if the patient genotypes were available from
the 2005 study, which compares affected (n¼26) and unaffected
(n¼26) patients who received 39–50Gy total dose, they could be
pooled with the UK data, as the experimental designs are so
similar.
The observed contributions to fibrosis risk of an early severe
acute reaction, which can trigger an inflammatory response, and
the TGFb1 (C-509T) SNP, which has been associated with
increased serum levels of the pro-inflammatory TGFb1 cytokine
following radiotherapy, are consistent with the established link
between fibrosis and inflammation (Awad et al, 1988; Zugmaier
et al, 1991; Anscher et al, 1997; Martin et al, 1997, 2000; Grainger
et al, 1999; Li et al, 1999). Additional genetic factors are
presumably responsible for the radiosensitivity that causes the
severe acute reaction and a number of variant genes have been
implicated in abnormal cell radiosensitivity (Moullan et al, 2003;
Chang-Claude et al, 2005; De Ruyck et al, 2005; Fernet and Hall,
2005), but none of the eight candidate gene SNP analysed in this
study was significantly associated with an early acute reaction. The
observed increased risk of telangiectasia in patients, who received
an additional 15Gy boost and/or are deficient in DNA repair owing
to the inheritance of a variant XRCC1 (R399Q) allele, is consistent
with the association of telangiectasia with vascular endothelial cell
damage (Quarmby et al, 1999).
Multiple testing has been performed on the same patient
samples so false positive or negative results are likely. As the
association between fibrosis and the TGFb1 ( 509) polymorphism
in breast cancer patients is a confirmation of previous independent
analyses (Quarmby et al, 2003; Andreassen et al, 2005), the
Boniferroni correction factor does not apply in this case, but the
association would still be significant (Po0.05) if the correction
factor was applied, as it would be for the association between
XRCC1 (R399Q) and telangiectasia. Nevertheless, the number of
patients assessed is relatively small, so further analyses using an
independent cohort of breast cancer patients are required to
confirm the apparent association between an early acute reaction
and late fibrosis/atrophy, and between the additional 15Gy boost,
XRCC1 (R399Q) and telangiectasia.
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